Can 2-Aticyto Complex be an Effective Agent for Recovery of The Symptoms and Enhancing Laboratory Parameters in COVID-19 Patients?


  •   Ferhan Kerget

  •   Buğra Kerget

  •   Alperen Aksakal

  •   Abdullah Osman Koçak


Background: SARS-CoV-2 (Covid-19) pandemic which was firstly identified in Wuhan/China in December 2019.There still exists no precise treatment for this pandemic yet despite many agents are tried in prophylaxis and treatment for Covid-19. In this study, we aimed to investigate the efficacy of 2-aticyto complex in clinical course in these patients.

Materials and Methods: 150 patients who applied to the Infection Diseases Polyclinics between dates September 2020-November 2020 having diagnosed with Covid-19 were included in our study. The patients were randomized into 2 groups (75 in each group) of which the first group only had the treatment of National Guideline and the second group had Viruthol® including 2-aticyto complex (at the dose of 27000 mcg/day) in addition to the treatment of the National Guideline. The laboratory parameters, clinical outcomes and the first day on which PCR result turned into negative of the patients were compared.

Results: In Viruthol® group, LDH, CRP, D-Dimer and ferritin levels were significantly decreased compared to the control group, while lymphocyte levels were higher. (p=0.02, p=0.001, p=0.01, p=0.02, p=0,001 respectively).  In addition to that, clinical symptoms such as fever, headache, weakness, loss of taste and smell and muscle-joint pain recovered more rapidly in contrast with the control group (p=0.001, p=0.05, p=0.001, p=0.001, p=0.001, respectively). PCR results of the Viruthol® group turned negative in a statistically significant shorter period of time with respect to the control group (p=0.001).

Conclusion: Viruthol® containing 2-aticyto complex may be an agent that can be used both symptomatic treatment and improving the clinical situation and recovery of the patients followed up for Covid-19.

Keywords: COVID-19, 2-aticyto complex, traditional medicine, treatment


Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. Jama. 2020;324(8):782-93.

Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. Jama. 2020;324(6):603-5.

Group RC. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine. 2020.

Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—preliminary report. The New England journal of medicine. 2020.

Benzie IF, Strain J. [2] Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods in enzymology. 299: Elsevier; 1999. p. 15-27.

Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. Journal of translational medicine. 2014;12(1):32.

Formica J, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food and chemical toxicology. 1995;33(12):1061-80.

Robaszkiewicz A, Balcerczyk A, Bartosz G. Antioxidative and prooxidative effects of quercetin on A549 cells. Cell biology international. 2007;31(10):1245-50.

Uchide N, Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications. Molecules. 2011;16(3):2032-52.

Nair MP, Kandaswami C, Mahajan S, Chadha KC, Chawda R, Nair H, et al. The flavonoid, quercetin, differentially regulates Th-1 (IFNγ) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2002;1593(1):29-36.

Shinozuka K, Kikuchi Y, Nishino C, Mori A, Tawata S. Inhibitory effect of flavonoids on DNA-dependent DNA and RNA polymerases. Experientia. 1988;44(10):882-5.

Labarrere CA, Woods J, Hardin J, Campana G, Ortiz M, Jaeger B, et al. Early prediction of cardiac allograft vasculopathy and heart transplant failure. American Journal of Transplantation. 2011;11(3):528-35.

Spedding G, Ratty A, Middleton Jr E. Inhibition of reverse transcriptases by flavonoids. Antiviral research. 1989;12(2):99-110.

Chusnie T, Lamb A. Antimicrobial activity of flavonoid. Int J Antimicrob Agent. 2005;26:343-56.

Pagani L. Effects of propolis flavonoids on virus infectivity and replication. Microbiologica. 1990;13:207-13.

Pilau MR, Alves SH, Weiblen R, Arenhart S, Cueto AP, Lovato LT. Antiviral activity of the Lippia graveolens (Mexican oregano) essential oil and its main compound carvacrol against human and animal viruses. Brazilian Journal of Microbiology. 2011;42(4):1616-24.

Mollova S, Fidan H, Antonova D, Bozhilov D, Stanev S, Kostova I, et al. Chemical composition and antimicrobial and antioxidant activity of Helichrysum italicum (Roth) G. Don subspecies essential oils. Turkish Journal of Agriculture and Forestry. 2020:44.

Czinner E, Lemberkovics É, Bihátsi-Karsai E, Vitányi G, Lelik L. Composition of the essential oil from the inflorescence of Helichrysum arenarium (L.) Moench. Journal of Essential Oil Research. 2000;12(6):728-30.

Do THA, Le HH, Kitsamone S, Nguyen TU, Nguyen QH. In vitro Antibacterial Activity of Quercetin Containing Extract from Hibiscus Sabdariffa L. Calyxes. 2016.

Daneshvar-Royandezagh S, Khawar K, Ozcan S. In Vitro micropropagation of garden thyme (Thymbra Spicata L. Var. Spicata L.) collected from southeastern turkey using cotyledon node. Biotechnology & Biotechnological Equipment. 2009;23(3):1319-21.

Duran N, Kaya A, Gulbol Duran G, Eryilmaz N. In vitro antiviral effect of the essential oils of Thymbra spicata L. on Herpes simplex virus type 2. ICAMS; 2012.

Demir F, Özcan M. Chemical and technological properties of rose (Rosa canina L.) fruits grown wild in Turkey. Journal of food engineering. 2001;47(4):333-6.

Ercişli S, Eşitken A. Fruit characteristics of native rose hip (Rosa spp.) selections from the Erzurum province of Turkey. New Zealand Journal of Crop and Horticultural Science. 2004;32(1):51-3.

Ziegler S, Meier B, Sticher O. Fast and selective assay of L-Ascorbic Acid in rose hips by RP-HPLC coupled with electrochemical and/or spectrophotometric detection. Planta medica. 1986;52(05):383-7.

Kılıçgün H, Altıner D. Correlation between antioxidant effect mechanisms and polyphenol content of Rosa canina. Pharmacognosy magazine. 2010;6(23):238.

Egea I, Sanchez-Bel P, Romajaro F, Pretel M. Replace synthetic additives in functional foods as a natural antioxidant. Plants Foods Hum Nutr. 2010;65:121-9.

Gökbulut İ, Öztürk FS. Gıda mikrokapsülasyonunda aljinat kullanımı. Batman Üniversitesi Yaşam Bilimleri Dergisi. 2018;8(1/2):16-28.

Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Progress in polymer science. 2012;37(1):106-26.

Sosnik A. Alginate particles as platform for drug delivery by the oral route: state-of-the-art. International Scholarly Research Notices. 2014;2014.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama. 2020;323(18):1824-36.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of infectious diseases. 2020;221(11):1762-9.

Vaninov N. In the eye of the COVID-19 cytokine storm. Nature Reviews Immunology. 2020;20(5):277.

Ali A, Mohamed S, Elkhidir I, Elbathani M, Ibrahim A, Elhassan A, et al. The Association of Lymphocyte count and levels of CRP, D-Dimer, and LDH with severe coronavirus disease 2019 (COVID-19): A Meta-Analysis. medRxiv. 2020.


Download data is not yet available.


How to Cite
Kerget, F., Kerget, B., Aksakal, A., & Koçak, A. O. (2021). Can 2-Aticyto Complex be an Effective Agent for Recovery of The Symptoms and Enhancing Laboratory Parameters in COVID-19 Patients?. European Journal of Medical and Health Science, 3(2), 35-39.